Cognition and fatigue in patients with relapsing multiple
sclerosis treated by subcutaneous interferon beta-1a: an
observational study SKORE

J 2017

Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE

BENEŠOVÁ, Yvonne and A. TVAROH

Basic information

Original name

Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE

Authors

BENEŠOVÁ, Yvonne (203 Czech Republic, guarantor, belonging to the institution) and A. TVAROH (203 Czech Republic)

Edition

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, LONDON, SAGE PUBLICATIONS LTD, 2017, 1756-2856

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.750

RIV identification code

RIV/00216224:14110/17:00098487

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1177/1756285616671882

UT WoS

000396377100002

Keywords in English

cognitive impairment; fatigue; interferon beta-1a; multiple sclerosis; treatment

Abstract

V originále

Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, which often causes progressive neurological disability. In addition to motor and sensory dysfunction, cognitive decline and fatigue are frequent manifestations of the disease. Fatigue is probably the most common symptom, with up to 90% of MS individuals reporting fatigue at some point. Cognitive impairment affects about 50% of patients and may be present at all MS stages. The aim of this observational study was to evaluate changes in cognition, fatigue, and disability status in 300 relapsing-remitting MS (RRMS) patients, treated with subcutaneous (sc) interferon (IFN) beta-1a over 2 years. Methods: The study was designed as an observational, multicentre, prospective, single-arm, phase IV study carried out in 13 MS centres in the Czech Republic. Cognition status was assessed using the Paced Auditory Serial Addition Task (PASAT), fatigue using the Fatigue Descriptive Scale (FDS), and disability using the Expanded Disability Status Scale (EDSS), at baseline, and after 6, 12 and 24 months. The percentage of patients with changed versus stable cognition, fatigue status and disability was calculated at each time point and the changes in these scores were evaluated. Results: The proportion of patients with cognitive improvement was higher compared with those with a stable or decreased PASAT scores at all time points, and the average cognitive performance improved during the follow-up period. Also the proportion of patients with stable or improved fatigue and EDSS scores was higher compared with those in which FDS or EDSS scores declined, this was found at all time points of the analysed sample. However, the direct effect of IFN beta-1a on cognition and fatigue cannot be concluded from this study. Conclusions: The results of this observational study have demonstrated a stable or improved cognitive performance, fatigue status, and disability level in the majority of RRMS patients treated with sc IFN beta-1a over a two-year follow-up period, in a real life setting, in the Czech Republic.

Citovat

BENEŠOVÁ, Yvonne and A. TVAROH. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. LONDON: SAGE PUBLICATIONS LTD, 2017, vol. 10, No 1, p. 18-32. ISSN 1756-2856. Available from: https://dx.doi.org/10.1177/1756285616671882.

@article{1396968,
   author = {Benešová, Yvonne and Tvaroh, A.},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1177/1756285616671882},
   keywords = {cognitive impairment; fatigue; interferon beta-1a; multiple sclerosis; treatment},
   language = {eng},
   issn = {1756-2856},
   journal = {THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS},
   title = {Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE},
   volume = {10},
   year = {2017}
}

TY  - JOUR
ID  - 1396968
AU  - Benešová, Yvonne - Tvaroh, A.
PY  - 2017
TI  - Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE
JF  - THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
VL  - 10
IS  - 1
SP  - 18-32
EP  - 18-32
PB  - SAGE PUBLICATIONS LTD
SN  - 17562856
KW  - cognitive impairment
KW  - fatigue
KW  - interferon beta-1a
KW  - multiple sclerosis
KW  - treatment
N2  - Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, which often causes progressive neurological disability. In addition to motor and sensory dysfunction, cognitive decline and fatigue are frequent manifestations of the disease. Fatigue is probably the most common symptom, with up to 90% of MS individuals reporting fatigue at some point. Cognitive impairment affects about 50% of patients and may be present at all MS stages. The aim of this observational study was to evaluate changes in cognition, fatigue, and disability status in 300 relapsing-remitting MS (RRMS) patients, treated with subcutaneous (sc) interferon (IFN) beta-1a over 2 years. Methods: The study was designed as an observational, multicentre, prospective, single-arm, phase IV study carried out in 13 MS centres in the Czech Republic. Cognition status was assessed using the Paced Auditory Serial Addition Task (PASAT), fatigue using the Fatigue Descriptive Scale (FDS), and disability using the Expanded Disability Status Scale (EDSS), at baseline, and after 6, 12 and 24 months. The percentage of patients with changed versus stable cognition, fatigue status and disability was calculated at each time point and the changes in these scores were evaluated. Results: The proportion of patients with cognitive improvement was higher compared with those with a stable or decreased PASAT scores at all time points, and the average cognitive performance improved during the follow-up period. Also the proportion of patients with stable or improved fatigue and EDSS scores was higher compared with those in which FDS or EDSS scores declined, this was found at all time points of the analysed sample. However, the direct effect of IFN beta-1a on cognition and fatigue cannot be concluded from this study. Conclusions: The results of this observational study have demonstrated a stable or improved cognitive performance, fatigue status, and disability level in the majority of RRMS patients treated with sc IFN beta-1a over a two-year follow-up period, in a real life setting, in the Czech Republic.
ER  -

BENEŠOVÁ, Yvonne and A. TVAROH. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE. \textit{THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS}. LONDON: SAGE PUBLICATIONS LTD, 2017, vol.~10, No~1, p.~18-32. ISSN~1756-2856. Available from: https://dx.doi.org/10.1177/1756285616671882.

Detailed Information on Publication Record